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Background: Technological advances including high-throughput sequencing have identiﬁed numerous tumor-
speciﬁc genetic changes in pediatric and adolescent cancers that can be exploited as targets for novel therapies.
Scope of review: This review provides a detailed overview of recent advances in the application of target-speciﬁc
therapies for childhood cancers, either as single agents or in combination with other therapies. The review sum-
marizes preclinical evidence on which clinical trials are based, early phase clinical trial results, and the incorpo-
ration of predictive biomarkers into clinical practice, according to cancer type.
Major conclusions: There is growing evidence that molecularly targeted therapies can valuably add to the arsenal
available for treating childhood cancers, particularly when used in combination with other therapies. Nonethe-
less the introduction ofmolecularly targeted agents into practice remains challenging, due to the use of unselect-
ed populations in some clinical trials, inadequate methods to evaluate efﬁcacy, and the need for improved
preclinical models to both evaluate dosing and safety of combination therapies.
General signiﬁcance: The increasing recognition of the heterogeneity ofmolecular causes of cancer favors the con-
tinued development of molecularly targeted agents, and their transfer to pediatric and adolescent populations.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
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Childhood cancers are rare, representing less than 1% of new cancer
diagnoses, however, they are still the leading cause of disease-related
death in children in industrialized countries such as the US [1].
Children's malignancies are generally treated with a combination of cy-
totoxic chemotherapy, radiation, surgery, and occasionally bone mar-
row transplant, which have markedly improved the overall 5-year
survival rate over the past decades from 50 to 60% for cases diagnosed
during the 1970s, to over 80% today [2].
The greatest contribution to better outcomes comes from ad-
vances in our understanding of the genetics of cancer [3–5], and
the discovery of molecular biomarkers and incorporation of novel
targeted agents has led to improved outcomes for cancer patients,
and decreases in both short- and long-term toxicities [6]. Some bio-
markers are routinely used for diagnostics (such as Ki-67 staining as
proliferation index) [7], risk-stratiﬁcation (MYCN ampliﬁcation in
neuroblastoma) [8] and monitoring (S100-beta in melanoma) [9].
Others are used to direct the use of targeted therapy, such as the fu-
sion tyrosine–kinase protein BCR–ABL for the use of imatinib in
chronic myeloid leukemia (CML) and Philadelphia chromosome
positive (Ph+) acute lymphoblastic leukemia (ALL) [10,11] or ana-
plastic lymphoma kinase (ALK) mutations (especially EML4–ALK
rearranged cancers) for the use of crizotinib, the ALK inhibitor ap-
proved for treatment of non-small cell lung cancer (NSCLC) [12,
13]. In summary, the genetic heterogeneity now recognized to un-
derpin pediatric and adolescent cancers may be exploited by agents
targeting these speciﬁc molecular/genetic lesions. A principal chal-
lenge is to now further expand the number of molecular targets in-
vestigated, and integrate conventional practices with the best
target-matched therapies. The aim of this review is to give an over-
view of recent advances in the application of “druggable” bio-
markers, and the use of target-speciﬁc therapies for childhood
cancers.2. Relevant biomarkers in childhood malignancies and novel
therapies
The role of germ-line mutations in explaining susceptibility to child-
hood cancer and genetic predisposition to familial malignancies is well
established [14], whereas the roles of somatic, acquired mutations have
become a central subject of study in more recent years. Cancer bio-
markers are now increasingly used to characterize human tumors and
to explain the heterogeneity that exists between different tumors. Such
heterogeneity is reﬂected by the wide range of sub-classiﬁcations (diag-
nosticmarkers) and risk-stratiﬁcations (prognosticmarkers) existing for
many cancer types, aswell as by the increasing number ofmolecules able
to forecast the response of patients to personalized therapies (predictive
markers) [15].
The following sections represent an overview of relevant markers
and matched therapies in pediatric tumors. A full list of the molecular
inhibitors reviewed is available in Table 1, while a schematic summary
of cancer pathway inhibition is shown in Fig. 1. Table 2 reports the fre-
quency of mutation/overexpression of some biomarkers relevant in
childhood cancer.2.1. Leukemias
Leukemias are the most common type of childhood cancers, ac-
counting for one-third of all cancers diagnosed in children. Among
them, ALL accounts for approximately three-quarters of all child-
hood leukemia diagnoses, while acute myelogenous leukemia
(AML) is 5 times less frequent. Chronic myeloid leukemia (CML)
and chronic lymphocytic leukemia are very rare in the pediatric pop-
ulation [16]. Several chromosomal abnormalities have been identi-
ﬁed in pediatric leukemias, including translocations such as t(9;22)
BCR–ABL, t(12;21) TEL–AML1, t(8;21) AML1–ETO and t(15;17)
PML–RARA [17].
Table 1
List of targets in childhood cancer discussed in this review with matching relevant targeted therapies.
Activity Target Agent Activity Target Agent
Monoclonal antibodies ERBB2 Pertuzumab Tyrosine kinase inhibitors ALK Crizotinib
Trastuzumab NVP-TAE684
EGFR Cetuximab BCR–ABL Imatinib
Nimotuzumab Dasatinib
VEGFR Bevacizumab c-KIT Dasatinib
IGF-1R Cixutumumab Sorafenib
Figitumumab Pazopanib
Teprotumumab MET Foretinib
Robatumumab Cabozantinib
Alpha IR-3 SU11274
AMG 479 K252a
R1507 EGFR/ERBB2 Erlotinib
EM164 Geﬁtinib
IMC-A12 Lapatinib
SCH 717454 Afatinib
Ser/Thr kinase inhibitors PI3K XL147 Canertinib
NVP-BEZ235 AEE788
NVP-BKM120 JAK/STAT3 AZD1480
GDC-0941 Ruxolitinib
IC87114 AG-490
PI103 PDGFRA Imatinib
AKT Perifosine Dasatinib
SF1126 Sorafenib
GSK690693 Sunitinib
MK-2206 Pazopanib
Aurora kinase Alisertib Foretinib
Tozasertib PDGFRB Dasatinib
AT9283 Sorafenib
BRAF Sorafenib Sunitinib
Vemurafenib Pazopanib
Selumetinib CP-673,451
mTOR Rapamycin VEGFR Sunitinib
Temsirolimus Dasatinib
PI103 Sorafenib
PP242 Vandetanib
Hedgehog pathway inhibitors SHH Vismodegib Cediranib
SEN450 Pazopanib
PF-5274857 PLK1 BI2536
SMO LDE225 BI6727
γ-Secretase inhibitors Notch RO4929097 LFM-A13
Histone deacetylase inhibitors HDAC Vorinostat GW843682X
Panobinostat SYK Fostamatinib
Entinostat C-61
Valproic acid TrkB Lestaurtinib
Romidepsin AZ64
Trichostatin A AZ623
Topoisomerase inhibitors TOP1 Topotecan FLT3 Lestaurtinib
Irinotecan Linifanib
Namitecan Sorafenib
Gimatecan Midostaurin
EZN-2208 AC220
Genz-644282 SU11657
TOP2 Etoposide IGF-1R BMS-754807
(R+)XK469 NVP-AEW541
MAP kinase pathway inhibitors MAP2K1–2 AZD6244 Chaperone inhibitors Hsp90 Geldanamycin
Sorafenib Tanespimycin
KRAS Tipifarnib Ganetespib
MEK Selumetinib AT13387
U0126 NVP-AUY922
ERK U0126 Alvespimycin
PARP inhibitors PARP Olaparib SNX-2112
Veliparib 17-AAG
ABT-888 17DMAP-GA
AG-014700 17AEP-GA
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The tyrosine kinase inhibitor imatinib (Gleevec) is a rare example of
an approved ﬁrst-line targeted treatment in adults and children, which
is indicated for the treatment of Philadelphia chromosome-positive
CML. Imatinib used in combination with cytotoxic chemotherapy was
also demonstrated to dramatically improve the 3-year event-free
survival of children and adolescents with Ph+ ALL [11]. AlthoughBCR–ABL kinase domain mutations have been reported in Ph+ ALL pa-
tients relapsing after imatinib, this may occur less frequently than in
adults treated with imatinib [18].
Following the success of imatinib, a number of other tyrosine kinase
inhibitors have emerged as potential therapies in pediatric leukemias.
Dasatinib is an oral multi-BCR–ABL and Src family inhibitor (also active
against c-KIT, platelet derived growth factor alpha/beta (PDGFRA/B)
Fig. 1. Schematic representation of twomain pathways aberrantly activated in pediatric tumors and corresponding targeted therapies.Molecular inhibitors andmonoclonal antibodies are
circled in purple and green, respectively.
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growth factor receptor (EGFR)/ERBB2) thatwas recently granted approv-
al for adult Ph-CML [19]. Dasatinib showed encouraging results in a phase
I trial in pediatric CML patients, with 6/8 evaluable patients achieving
partial or complete cytogenetic responses [20], and is currently in phase
II study (NIH trial NCT01460160). Sorafenib is a small molecule that in-
hibits several tyrosine (VEGFR and PDGFR) and serine/threonine kinases
(MAP kinases), and has been approved for the treatment of renal cell andTable 2
Frequency (%) of positivity by immunohistochemistry or mutation of relevant biomarkers in c
Target Childhood cancer IHC (%)
ALK Neuroblastoma 23.5% (stage 1–2) 77% (stage
Rhabdomyosarcoma 53% (ARMS) 23% (ERMS)
Ewing sarcoma 69%
Glioblastoma 82% (in cell lines)
BRAF Low-grade glioma –
cMET Glioblastoma 29% (pediatric and adult coh
Rhabdomyosarcoma 35%
Ewing sarcoma 86%
EGFR Glioma 80%
Neuroblastoma 95%
Osteosarcoma 59%
Wilms tumor 38%
Rhabdomyosarcoma 47%
ERBB2 Medulloblastoma/ATRT 57.5%
Rhabdomyosarcoma 33%
Wilms tumor 39.1%
Osteosarcoma 18.8%
MGMT Glioblastoma 11%
PDGFRA DIPG 36%
Glioblastoma 18%
Neuroblastoma 100%
Ependymoma 29.2%
Rhabdomyosarcoma N40%
PDGFRB Rhabdomyosarcoma N40%
Glioma 78.9%
Ewing sarcoma 79%
Astrocytoma 31%
Neuroblastoma 72.5%
PIK3CA Neuroblastoma 92%
PTEN Osteosarcoma –
Neuroblastoma 100%
SPARC Osteosarcoma 96.3%
VEGF ALL 21%
AML 38%
– indicates not studied.hepatocellular carcinoma [21]. In a phase 1 study of single-agent sorafe-
nib, two acute myeloid leukemia (AML) patients with FLT3 internal tan-
dem duplication achieved dramatic reductions in bone marrow blasts,
andproceeded to bonemarrow transplantation [22]. Sorafenib is current-
ly being evaluated for incorporation into standard chemotherapy regi-
mens in a Children's Oncology Group multi-center study [22]. Other
tyrosine kinase inhibitors directed against FLT3 such as AC220 and
midostaurin (PKC412) are in phase I or I/II trials for relapsed or refractoryhildhood cancers. References are listed in Supplemental document (S1).
Reference Mutation (%) Reference
3–4) [I] 10.4% [II]
[III] 16% (deletion) [IV]
[V] 16% [V]
[VI] –
15% (V600E) [VII]
ort) [VIII] –
[IX] –
[V] 9% [V]
[X] 17% (deletion) [XI]
[XII] infrequent [XII]
[XIII] –
[XIV] –
[XV] 13% [XVI]
[XVII] –
[XV] –
[XVIII] –
[XIX] –
[XX] –
[XXI] 5% [XXII]
[XXIII] 14% [XXII]
[XXIV] –
[XXV] –
[XXVI] –
[XXVI] –
[X] 0% [XI]
[XXVII] 0% [XXVIII]
[XXIX] –
[XXX] –
[XII] Infrequent [XII]
20% (deletion) [XIII]
[XII] 39% (deletion) [XII]
[XXXI] –
[XXXII] –
[XXIV] –
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while SU11657 is in preclinical development [23]. Overall, primary pedi-
atric AML samples with FLT3 or KIT mutations were signiﬁcantly more
sensitive to SU11657 than wild-type AML samples [23].
In 2011, the JAK/STAT inhibitor ruxolitinibwas approved for the treat-
ment of intermediate or high-riskmyeloﬁbrosis [24]. However, recent re-
sults demonstrated its in vivo activity in Ph-ALL xenograft models, when
administered in combination with the mammalian target of rapamycin
(mTOR) inhibitor rapamycin [25]. Fostamatinib is an experimental drug
targeting spleen tyrosine kinase (SYK), and is in clinical trial for
rheumatoid arthritis (NCT01242514), autoimmune thrombocytopenia
(NCT00706342) and lymphoma (NCT00798096). Dietary fostamatinib
was reported to reduce the burden of leukemic blasts in mice injected
intrafemorally with primary B-ALL samples [26]. Recently, a nanoscale li-
posomal formulation of another selective SYK inhibitor C61 exhibited po-
tent anti-leukemic activity against patient-derived ALL xenografts in vivo
[27]. The same authors described the in vivo chemosensitizing and
apoptosis-promoting activity of LFM-A13, a dual-function inhibitor of
Bruton's tyrosine kinase and polo-like kinase 1 (PLK1), against pediatric
ALL [28].
2.1.2. Serine/threonine kinase inhibitors
A second class of molecular inhibitors that has been employed in the
treatment of pediatric leukemias is one directed against serine/threonine
kinases such as MAP kinase, phosphatidylinositol 3′-kinase (PI3K) and
Aurora kinase. The MAP kinase pathway is often activated in pediatric
malignancies [29] and other inhibitors have been developed to target
this speciﬁcally. Among them, the farnesyl transferase inhibitor tipifarnib
was tested in a phase I clinical trial of pediatric patients with advanced,
heavily pretreated leukemia, where no objective responses were ob-
served in 23 evaluable patients [30]. GDC-0941 and IC87114, two inhib-
itors of PI3K directed against the alpha and delta subunits, respectively,
reduced granulocyte macrophage-colony stimulating factor (GM-CSF)
hypersensitivity in amousemodel of juvenilemyelomonocytic leukemia
[31]. However the pan-PI3K inhibitor XL147 (SAR245408) signiﬁcantly
improved event-free survival in only 2/7 pediatric leukemia xenografts,
and produced no objective responses [32].
Aurora kinase inhibitors have producedmore encouraging results in
childhood leukemia in the preclinical setting. The pan-Aurora kinase in-
hibitor AT9283 produced target kinase inhibition [33] and inhibited the
growth and survival of pediatric leukemia cell lines [34], although a sig-
niﬁcant correlation between AT9283 and target protein expression
could not be established [34]. Similarly, the Aurora kinase A (AURKA)
inhibitor alisertib (MLN8237) produced complete responses in 6/6 ALL
xenograft models, although there was again no correlation between
AURKA copy number or expression [35]. Objective responses were sub-
sequently demonstrated in 3 additional ALL xenografts with low AURKA
expression [36]. AT9283 reached phase I/II clinical trial for pediatric re-
lapsed or refractory acute leukemia (NCT01431664), which is still in
progress.
2.1.3. Histone deacetylase (HDAC) and heat shock protein 90 (Hsp90)
inhibitors
Small molecules directed against other targets, including histone
deacetylases (HDAC) and heat shock protein 90 (Hsp90), have been
evaluated in the preclinical setting. Vorinostat (SAHA), an HDAC inhib-
itor approved for the treatment of refractory cutaneous T-cell lympho-
ma, produced no objective responses in 8 ALL xenografts [37]. No
objective responses were similarly obtained in 6 pediatric leukemia pa-
tients in a phase I clinical trial [38]. Vorinostat is now being evaluated in
combination with the demethylating agent decitabine and chemother-
apy in relapsed ALL patients (NCT01483690). Hsp90 inhibitors reduce
the stability of associated client proteins, and may thereby exert anti-
oncogenic effects. Tanespimycin (17-AAG), a member of the gelda-
namycin family of antibiotics, rendered a pre-B ALL patient-derived
cell line signiﬁcantly more sensitive to imatinib, and reduced the IC50values for a number of other chemotherapeutic agents [39]. However
ganetespib, another Hsp90 inhibitor, showed no signiﬁcant activity as
a single agent towards 4 JAK-mutated ALL xenografts [40].
2.1.4. DNA topoisomerase inhibitors
Among theDNA topoisomerase 1 (TOP1) inhibitors, topotecan is one
of the best characterized and one of the ﬁrst to enter clinical trials.
Topotecan is a derivative of the natural alkaloid camptothecin, and is
currently approved for the treatment of adult ovarian and cervical can-
cer, as well as small cell lung cancer [41]. Topotecan has also been suc-
cessful in clinical trials against relapsed pediatric ALL [42] and AML [43]
in combination with a variety of chemotherapy agents. Irinotecan is an-
other TOP1 inhibitor that has been approved for the treatment of colo-
rectal cancer [44]. A panel of 6 patient-derived pediatric ALL cell lines
was shown to be more sensitive to irinotecan than topotecan, based
on measured IC50 values [45]. Recently, a combination of irinotecan,
the TOP2 inhibitor etoposide and cytarabine entered a phase I clinical
trial for pediatric refractory or relapsed ALL and AML (NCT01239485).
Etoposide in combination with clofarabine and cyclophosphamide has
previously been tested in phase I and II studies of refractory or relapsed
ALL or AML, resulting in complete remissions (with or without platelet
count recovery) in 16/25 (64%) patients in the phase I trial [46], and in
11/25 (44%) patients in the phase II trial [47]. This treatment regimen
therefore produced encouraging response rates, and sustained remis-
sion in refractory or relapsed patients [47].
2.1.5. Proteasome inhibitors
The proteosome inhibitor bortezomib exerts anti-tumor activity by
affecting a number of physiological processes, including preventing
degradation of pro-apoptotic factors. Bortezomib treatment as a single
agent showed encouraging preclinical results, signiﬁcantly increasing
event-free survival in 4/7 ALL xenograft models [48], but produced no
objective clinical responses in a phase I clinical trial of 12 refractory or
relapsed ALL or AML patients [49]. Because of bortezomib's distinctive
mechanism of action, there was interest in combining this with stan-
dard anti-leukemia agents, and synergistic or additive interactions
were demonstrated with range of chemotherapeutic agents in T-ALL
and pre-B ALL cell lines in vitro [50]. In a phase I trial, bortezomib
added to standard therapy for relapsed pediatric ALL induced complete
responses in 6/9 patients [51], with 16/22 (73%) relapsed ALL patients
achieving complete remission in the subsequent phase II trial, which
met the pre-deﬁned criteria for early trial closure [52]. The study au-
thors recommended evaluating the addition of bortezomib in random-
ized studies on childhood pre-B ALL protocols [52].
2.1.6. Immunotherapy
Understanding the role of the immune system in tumor surveillance
has led to novel approaches for cancer treatment, such as unconjugated
and conjugated monoclonal antibodies (mAbs), and chimeric antigen
receptors (CARs) [53]. Hematopoietic differentiation antigens represent
a major tumor antigen class for the treatment of leukemia and lympho-
ma, which may be relevant to both adult and pediatric diseases. In a
phase II window trial, 36/87 (41.4%) pediatric B-cell non-Hodgkin's
lymphomapatients responded to the anti-CD20mAb rituximab as a sin-
gle agent [54], producing at least objective responses at an index site,
and no other signs of progression. Combining rituximab with chemo-
therapy produced a 60% response rate in 12/20 patients with relapsed
and refractory pediatric B-cell non-Hodgkin's lymphoma or mature B-
cell leukemia [55]. In contrast, the anti-CD52 mAb alemtuzumab in-
duced complete remission in only 1/13 (7.6%) relapsed ALL patients,
and was not recommended for further use as a single agent [56].
However, in combination with busulfan and ﬂudarabine, alemtuzumab
improved the engraftment rate in pediatric patients undergoing hema-
topoietic stem cell transplantation [57]. As unconjugated antibodies
have been approved to treat a number of adult malignancies [58],
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Payload-delivery mAbs conjugated with cytotoxic agents, includ-
ing antibody–immunotoxin and antibody–drug conjugates, and
radio-immunoconjugates, could all improve the potency of unconju-
gated mAbs, particularly in immunocompromised patients [59,60].
Gemtuzumab ozogamicin is an anti-CD33 mAb conjugated to a deriva-
tive of the cytotoxic antibiotic calicheamicin, and has been comprehen-
sively studied in adults. In a phase I study as a single agent, 8/29 (28%)
pediatric AML patients with relapsed or refractory disease achieved
complete remission, with or without platelet count recovery [61].
Higher proportions of AML patients (40% and 55%) achieved complete
remissions in a larger subsequent dose de-escalation study where
gemtuzumab ozogamicin was combined with standard chemotherapy
[62]. In relapsed and refractory pediatric ALL patients, the anti-CD22
immunotoxinmoxetumomab pasudotox produced complete responses
in 4/17 (24%) patients [63], and the anti-CD22 calicheamicin conjugate
inotuzumab ozogamicin produced complete responses in 3/5 relapsed
pre-B ALL patients, all of which expressed CD22 [64]. There is further
scope for testing other conjugated mAbs in pediatric leukemia, as the
anti-CD19 mAb–drug conjugate SAR3419 delayed progression in 4/4
pre B-ALL and 3/3 infant mixed lineage leukemia xenograft models as
a single agent [65].
T-cell engaging antibodies represent new therapeutic approaches
for treating leukemia and lymphoma, with the bi-speciﬁc T-cell engag-
ing (or BiTE®) antibody blinatumomab now being tested in pediatric
leukemia patients, following encouraging results in adults [66].
Blinatumomab is a fusion of two single chain antibodies to CD19 and
CD3, and thereby brings malignant B cells into close proximity with
CD3-positive T cells [66]. Blinatumomab treatment of 3 pediatric pa-
tients with refractory pre-B ALL rapidly induced complete remissions,
whichwasmaintained in one case for over 23 months [67]. Preliminary
data from the ﬁrst phase I clinical trial of blinatumomab indicate com-
plete remissions in 11/34 (32%) relapsed/refractory pre-B ALL patients
[68], although the associated side effect proﬁle, which can include cyto-
kine release syndrome, requires careful management [66]. The phase II
NCT01471782 clinical trial to investigate the pharmacokinetics, phar-
macodynamics and safety of escalating doses of blinatumomab in pedi-
atric and adolescent patients with relapsed/refractory pre-B ALL is
ongoing, and estimated to complete in 2016.
Chimeric antigen receptors (CARs) represent an exciting new form of
targeted therapy that confers the targeting speciﬁcity ofmAbs to cytotox-
ic T cells, theﬁrst of whichwere reported some 25 years ago [69]. Second
and third generations of CARs have been developed by the addition of
one or two co-stimulatory molecules [70], with the goal of improving
the in vivo persistence of the transferred T cells [71]. B-cell malignancies
are particularly amenable to CAR therapy, as mAbs are available to target
B-cell surface antigens, and temporary loss ofmature B-cells is an accept-
able on-target, off-tumor effect [70]. A recently reported trial of CD19-
targeting CAR T-cells showed the feasibility and safety of this approach
[72], while two pediatric patients with relapsed B-ALL treated with
CD19-speciﬁc CAR T-cells were reported to achieve remission [73]. Nu-
merous trials of T cells engineeredwith CD19-directed CARs are currently
undergoing in ALL patients (NCT00608270, NCT01593696, see also [70]
for other examples).
2.1.7. Leukemia summary
Over the past 50 years, outcomes for pediatric leukemia patients
have dramatically improved by varying the schedules and doses of
established cytotoxic drugs, albeit at the cost of severe toxicity [53,74].
However, there are encouraging signs that this situation is changing,
largely through the exploitation of targets such as protein kinases
known from adult oncology [74]. The presence of tissue restricted anti-
gens on hematopoietic cells also provides numerous options for
targeting B-cell malignancies in children, with acceptable on-target
side effects, and the accessibility of leukemic cells within the circulationmakes leukemias particularly suited to antibody-based treatment strat-
egies [53,70]. Evolution of resistant diseasemay be avoided by the use of
less selective kinase inhibitors, and of targeted agents that can access
sanctuary sites such as the CNS [18].
2.2. Neuroblastoma
Neuroblastoma originates from primordial neural crest cells and is
the most common extra-cranial malignant childhood tumor. It is a het-
erogeneous malignancy classiﬁed into low-, intermediate-, or high-risk
categories based upon clinical and biological features correlating with
prognosis. Low- and intermediate-risk patients have an overall survival
exceeding 90%, while newly diagnosed high-risk neuroblastoma and
patients whose disease recurs show survival rates of 50% and less than
10%, respectively [75].
2.2.1. MYCN
MYCN is a member of the MYC transcription factor family, with
MYCN gene ampliﬁcation being strongly associated with poor outcome
in neuroblastoma.MYCN ampliﬁcation is present in approximately 20%
of neuroblastomas and nearly half of high-risk cases [8]. As such, MYCN
represents a prime therapeutic target in neuroblastoma, and small mol-
ecules have been developed to target MYC family members as well as
MYC DNA binding functions, transcription and protein–protein interac-
tions. 10058-F4, a novel drug that inhibits MYC–MAX interactions, pro-
duced modest survival beneﬁt in a MYCN-dependent neuroblastoma
mouse model (TH-MYCN) [76]. Recently, the bromodomain and extra
terminal (BET) family adaptor proteins were shown to localize toMYC
promoters [77], with BET proteins binding acetylated histones associat-
ed with open chromatin and transcriptional activation [78]. Use of the
small molecule BET inhibitor JQ1 induced MYC down-regulation [77,
79] and improved survival of mice bearing MYCN-ampliﬁed BE(2)-C
neuroblastoma or primary human neuroblastoma xenografts, and of
TH-MYCN transgenic mice [80]. A JQ1 derivative has now entered
phase I/II clinical trial for the treatment ofMYCN-ampliﬁed cancers, in-
cluding neuroblastoma (NCT01587703). Myc was also shown to cause
DNA damage through induction of replication stress, with the resulting
replication arrest being partially overcome by Chk1 inhibition [81].
CHK1 transcript levels were subsequently found to be signiﬁcantly
higher in MYCN-ampliﬁed versus non-ampliﬁed neuroblastomas, and
neuroblastoma cell lines were more sensitive to CHK1 inhibition than
controls [82]. CCT244747, a highly selective, orally active CHK1 inhibi-
tor, showed single-agent activity in the TH-MYCN transgenic mouse
neuroblastoma model, as evidenced by signiﬁcantly reduced tumor
weights after 7 days of treatment [83]. Future clinical studies will now
determinewhether agents targetingMYCN activity or downstream cel-
lular processes could improve outcomes inMYCN-ampliﬁed neuroblas-
toma patients.
2.2.2. Differentiating agents and immunotherapy
In childrenwith high-risk neuroblastoma, treatmentwith the differ-
entiating agent 13-cis-retinoic acid reduces the risk of recurrence after
high-dose chemotherapy and stem cell transplant [84]. Fenretinide, a
synthetic retinoid, was shown to induce apoptosis in neuroblastoma
cells in vitro [85] and, as a consequence, entered phase I and II clinical
trials for the treatment of refractory or recurrent neuroblastoma. How-
ever, the best reported response was stable disease, potentially due to
the scarce bioavailability of this molecule [86,87]. Novel fenretinide for-
mulations with improved bioavailability have been evaluated in pre-
clinical studies [88] and are currently in phase I clinical trials in
recurrent or refractory neuroblastoma patients (NCT00295919).
In the last decade, the addition of disialoganglioside (GD2) immuno-
therapy to retinoid maintenance therapy for high-risk neuroblastoma
has constituted a major advance, where typically 50% of this group of
patients die from their disease [89]. Disialoganglioside GD2 is a surface
glycolipid antigen normally found on neurons, peripheral pain ﬁbers
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ma cells. Clinical use of the murine anti-GD2 mAb 3F8 was frustrated by
severe side effects, and the development of human anti-mouse antibod-
ies [89]. A subsequent phase III trial of a chimeric human–murine anti-
GD2 mAb ch14.18 in high-risk neuroblastoma patients who had previ-
ously received intensivemulti-model therapy, demonstrated signiﬁcant-
ly improved event-free and overall survival in the immunotherapy
group, and met the criteria for early stopping [90]. To improve the
side-effect proﬁle associated with ch14.18, a humanized anti-GD2 mAb
was developed with a single point mutation (K322A) to reduce
complement-dependent lysis [91]. In summary, anti-GD2 antibodies
are likely to provide a major shift in the treatment of minimal residual
disease in high-risk neuroblastoma patients, once these are commercial-
ly available [90].2.2.3. PI3K/AKT/mTOR inhibitors
The PI3K/AKT/mTOR pathway is one of the most potent pro-
survival signaling cascades [92] and its aberrant activation is a com-
mon event in high-risk neuroblastoma patients [93]. Perifosine is an
alkylphospholipid inhibitor of the PI3K/AKT pathway, which when
used as a single agent, signiﬁcantly improved the survival of mice
bearing human neuroblastoma xenografts (AS, NGP, BE2, and
KCNR) [94], and showed synergistic effects in combination with
etoposide [95]. Results from these studies paved the way for a
phase I clinical trial of perifosine in refractory or recurrent pediatric
solid tumors (NCT00776867). Preliminary results indicate encourag-
ing perifosine activity in neuroblastoma patients, in the absence of
signiﬁcant toxicity [96].
Rapamycin (sirolimus) is a natural macrolide antibiotic with immu-
nosuppressive and antiproliferative properties. Its anti-cancer activity
derives from its ability to bind the cytosolic protein FKBP12, inhibit
themTOR complex 1, and as a consequence, inhibit VEGF and angiogen-
esis [97]. Temsirolimus, a derivate of rapamycin, is an approved drug for
the treatment of renal cell carcinoma, and has been tested as a single
agent in phase I and II trials for pediatric solid tumors [98,99]. After
12 weeks of temsirolimus treatment, 6/19 (32%) neuroblastoma pa-
tients showed stable disease, supporting further exploration of
temsirolimus in combination with other therapies [99].
Recent in vivo studies reported the anti-proliferative ability of four
novel drugs active against the PI3K/AKT/mTOR pathway, namely
SF1126, XL147, PI103 and NVP-BEZ235 [32,100–104]. The peptidic pro-
drug inhibitor SF1126 was demonstrated to interfere with the pAKT–
MDM2 axis, and tomarkedly inhibit the growth of neuroblastoma xeno-
grafts [100]. SF1126 is also in phase II trial for adult solid tumors
(NCT00907205). XL147, which is in phase I and II trials for adult cancers
(NCT01587040), signiﬁcantly improved event-free survival in 6/6 neuro-
blastomaxenografts, but produced no objective responses [32]. PI103 is a
dual PI3K/mTOR inhibitor that was demonstrated to cooperate with
TNF-related apoptosis-inducing ligand (TRAIL) to synergistically induce
apoptosis in neuroblastoma cells (SH-EP, LAN-5 and CHP-212) [101]
and to delay growth of MYCN-ampliﬁed SK-N-BE(2) neuroblastoma
xenografts [102]. Another dual PI3K/mTOR inhibitor NVP-BEZ235
showed increased sensitivity towards MYCN-ampliﬁed neuroblastoma
cells in vitro, and reduced tumor angiogenesis through destabilization
of MYCN protein levels in vivo, thereby signiﬁcantly improving the
survival of tumor-bearing TH-MYCNmice [103]. Synergistic interactions
were subsequently demonstrated between NVP-BEZ235 and the
lysosomotropic agent chloroquine in vitro, triggering lysosome-
mediated apoptosis through lysosome enlargement and the generation
of reactive oxygen species (NVP-BEZ235) and lysosomalmembrane per-
meabilization (chloroquine) [104]. NVP-BEZ235 is yet to enter clinical
trial for neuroblastoma, with phase I trials involving adult patients cur-
rently ongoing. As chloroquine is in clinical use, this could be feasibly
be combinedwithNVP-BEZ235 for neuroblastoma therapy [104], follow-
ing preclinical testing in vivo.2.2.4. Tyrosine kinase and HDAC inhibitors
Some 8% of all neuroblastoma cases and over 12% of high-risk pa-
tients harbor alterations in the tyrosine kinase ALK sequence [105,
106], and 23.5% of stage 1–2 and 77% of stage 3–4 patients show high-
level ALK immunoreactivity [107]. Crizotinib, an ALK andMET inhibitor,
entered a phase I/II clinical trial as single agent for pediatric refractory
solid tumors, producing several complete responses and prolonged sta-
ble disease in both ALK-positive and unknown ALK status neuroblasto-
ma patients [108]. A combination phase I trial of crizotinib and
conventional chemotherapy is currently ongoing (NCT01606878).
Among other ALK inhibitors, LDK378 demonstrated greater potency
over crizotinib, and anti-tumor activity in crizotinib-resistant adult tu-
mors [109]. A pediatric phase I clinical trial with LDK378 as a single
agent is also underway (NCT01742286).
Several drugs synthesized to speciﬁcally inhibit other tyrosine ki-
nases have also been tested in clinical trials for neuroblastoma. The
ERBB2/EGFR inhibitors erlotinib and geﬁtinib have completed phase I
clinical trials in combination with temozolomide [110] or topotecan
and cyclophosphamide [111], respectively, with both trials reporting
prolonged stable disease in some neuroblastoma patients. A phase II
trial of erlotinib in combination with pertuzumab (a mAb against
ERBB2) was terminated due to high toxicities (NCT00947167), while a
phase II trial of geﬁtinib in combinationwith irinotecan reported partial
responses in only 5/19 (26%) high-risk neuroblastoma patients [112].
Canertinib (CI-1033), a pan-ERBB inhibitor, reduced the growth and
size of SK-N-SH neuroblastoma xenografts to a greater extent than erlo-
tinib [113].
Neurotrophin receptors of the tyrosine kinase (Trk) family play im-
portant roles in neuroblastoma etiology, with TrkB expression being as-
sociated with unfavorable outcomes andMYCN ampliﬁcation. A phase I
trial of lestaurtinib (a FLT3 and TrkB inhibitor) supported its safe use as a
single agent in children with refractory neuroblastoma, warranting fur-
ther evaluation [114]. Similarly, Iyer and colleagues reported signiﬁcant
improvements in the survival of mice bearing SH-SY5Y xenografts
when lestaurtinib was combined with topotecan plus cyclophospha-
mide [115]. Two other TrkB inhibitors AZ64 and AZ623 have also been
tested in neuroblastoma xenografts. AZ64 enhanced the response to
irinotecan [116], while AZ623 inhibited tumor growth, and prolonged
the inhibition of tumor regrowth when combined with topotecan
[117]. The same authors found that the VEGFR inhibitor, vandetanib
(ZD6474), in combinationwith 13-cis-retinoic acid, reduced tumor vas-
cularity and induced apoptosis in neuroblastoma xenografts [118]. Van-
detanib also reduced the growth of SK-N-SH neuroblastoma xenografts
by 85% as a single agent [119]. VEGFR is also the target of cediranib
(AZD2171), an investigational drug in phase III clinical trial for a number
of adult malignancies including glioblastoma (NCT00777153), NSCLC
(NCT00245154) and colorectal cancer (NCT00384176). Two separate
in vivo studies demonstrated that cediranib delayed the growth of neu-
roblastoma xenografts as a single agent [120], but reduced the event-
free survival of NB-EBc1 neuroblastoma xenografts associated with cy-
clophosphamide treatment alone when used in combination [121].
Polo-like 1 (PLK1) is another kinase recently identiﬁed as a potential
therapeutic target in neuroblastoma [122]. BI2536 and BI6727, two
PLK1 inhibitors in clinical trial for adult malignancies (NCT00526149
and NCT01022853, respectively), were shown to be cytotoxic towards
neuroblastoma cells (NB12, NB88R2, and NB122R), and BI2536 signiﬁ-
cantly inhibited the growth of neuroblastoma xenografts as a single
agent, and in combination with irinotecan [122]. The PLK1 inhibitor
GW843682X also blocked the proliferation of a panel of pediatric cancer
cell lines in vitro, including IMR-5 and SMS-KCNMYCN-ampliﬁed neuro-
blastoma cells [123].
PDGFR inhibitors are a family of novel drugs that have been widely
tested in neuroblastoma cell lines and mouse models. For example,
dasatinib showed cytostatic and anti-migratory activity in vitro [124]
but only partial tumor growth inhibition in vivo [125]. More encourag-
ing results have come from in vivo testing of pazopanib, sorafenib and
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sarcomas in adults [126], showed high anti-tumor and anti-angiogenic
activity when administered as metronomic chemotherapy in combina-
tionwith topotecan in SK-N-BE and SH-SY5Y neuroblastoma xenografts
[127]. Sorafenib inhibited the growth of neuroblastoma xenografts by
targeting both cell proliferation and angiogenesis [128]. Sunitinib, a
PDGFR (and VEGFR) inhibitor approved for renal cell carcinoma and
imatinib-resistant gastrointestinal stromal tumor [129], showed anti-
tumor activity both in early stage tumor formation and in progressive
metastatic neuroblastoma in SK-N-BE and SH-SY5Y xenografts [130].
Other tyrosine kinase inhibitors with activity against neuroblastoma
are those directed against the JAK/STAT axis and Aurora kinase.
AZD1480, a JAK/STAT3 inhibitor [131], was recently demonstrated to
show anti-tumor activity, and to decrease expression of STAT3 and
downstream targets in KCNR and SH-SY5Y neuroblastoma xenografts
[132]. Alisertib, an AURKA inhibitor, disruptedmitotic spindle assembly
and the mitotic checkpoint in neuroblastoma cell lines (NB-1643, NB-
EBC1, CHLA-90 and CHLA-136), and induced maintained complete
responses in a panel of 7 neuroblastoma xenograft models [35]. These
results provided the preclinical rationale for alisertib to enter phase II
clinical trials, either as a single agent (NCT01154816, for neuroblastoma
and sarcomas), or in combination with temozolomide and irinotecan
(NCT01601535, for neuroblastoma). Thus far, the only reported result
for neuroblastoma patients indicated stable disease as the best response
to alisertib single-agent therapy [133]. In IMR-32 neuroblastoma cells,
alisertib showed additive cytotoxic effects in combination with the
HDAC inhibitor vorinostat [134]. This supported the inclusion of
vorinostat in clinical trials for refractory or recurrent pediatric solid tu-
mors including neuroblastoma. Either as a single agent [38] or com-
bined with the proteasome inhibitor bortezomib [135], vorinostat was
demonstrated to be safe, and produced stable disease or complete re-
sponse in some neuroblastoma patients. Other HDAC inhibitors includ-
ing romidepsin and entinostat have been tested in KCNRneuroblastoma
xenografts, resulting in tumor growth inhibition and apoptosis [136,
137].
2.2.5. DNA topoisomerase inhibitors
Topoisomerase poisons such as irinotecan have been successfully
used to treat neuroblastoma patients [112] and proved active in phase
I and II trials in combination with temozolomide [138,139]. The combi-
nation of irinotecan with temozolomide is considered standard therapy
in relapsed high-risk neuroblastoma patients [140]. Recent studies have
reported the NF-κB pathway and the B-MYB/MYCN axis as targets of
topotecan in neuroblastoma cells [141,142] and clinical trials have
shown encouraging responses to topotecan in neuroblastoma patients.
For example, topotecan and etoposide administered together induced
partial or complete remissions in 17/36 (47%) patients [143], with the
addition of cyclophosphamide inducing partial or complete responses
in 19/31 (61%) relapsed and 8/11 (72%) newly diagnosed neuroblasto-
ma patients [144]. In a more recent trial, topotecan in combination
with cyclophosphamide produced signiﬁcantly better progression-free
survival than topotecan as a single regimen [145]. Etoposide has also
been employed in numerous trials for refractory and relapsed neuro-
blastoma, with encouraging results [146], while preclinical studies
have examined other TOP1 and TOP2 inhibitors including namitecan,
gimatecan and the investigational drugs EZN-2208, and (R+)XK469
[147–151]. Namitecan demonstrated antitumor activity in SK-N-AS
neuroblastoma xenografts, inducing apoptosis and tumor shrinkage,
and a signiﬁcant enhancement of platinum agent activity [147], where-
as gimatecan produced signiﬁcant regression of SK-N-DZ neuroblasto-
ma xenografts in vivo [148]. This latter result supported the superior
activity of gimatecan versus irinotecan and topotecan, in terms of pro-
ducing growth arrest in 5 human neuroblastoma cell lines (SK-NDZ,
BE(2)M17, LAN-1, RNGA, SK-N-BE(2)c) [149]. Similarly, EZN-2208, a
PEGylated version of irinotecan, was superior to standard irinotecan in
inducing tumor regression and preventing tumor relapse in a panel ofneuroblastoma mouse xenografts [150], while (R+)XK469 induced
growth inhibition of neuroblastoma xenografts and produced disease
stabilization in a case-report of a neuroblastoma patient [151].
2.2.6. Polyamine inhibitors
Polyamines are multifunctional polycations that are indispensible for
cancer cell survival, inﬂuencing a range of biological processes including
DNA synthesis and stability, replication, transcription and translation, ri-
bosome biogenesis, and protein phosphorylation [152]. Ornithine decar-
boxylase 1 (ODC1), the ﬁrst and rate limiting enzyme in polyamine
biosynthesis is a well characterized Myc and MYCN target gene, and
high ODC1 levels were signiﬁcantly associated with reduced event-free
survival in neuroblastoma patients [153]. Diﬂuoromethylornithine
(DFMO), a suicide inhibitor of ODC1, demonstrated inhibition of tumor
growth in TH-MYCNmice and synergizedwith chemotherapy in treating
established tumors [154]. Clinical trials employing DFMO as a single
agent or as part of combination treatment for neuroblastoma are ongo-
ing (NCT01059071; NANT 2012-01). In addition to DFMO, a number of
other polyamine depletion agents have been identiﬁed [152], although
their clinical potential remains to be determined.
2.2.7. Hsp90 inhibitors
A ﬁnal category of targeted therapies tested on neuroblastoma
models are those directed against Hsp90, including geldanamycin,
SNX-2112 and ganetespib. Geldanamycin treatment depleted key
anti-apoptotic proteins in SK-N-SH neuroblastoma cells [154], and
both geldanamycin and SNX-2112 demonstrated marked single-agent
activity, and synergistic [154] or greater than additive activity with cis-
platin [155] in BE(2)-C [154] or SK-N-SH and IMR-32 cells, respectively
[155]. However, ganetespib demonstrated limited activity as a single
agent against NB-1643 neuroblastoma xenografts in vivo [40].
2.2.8. Neuroblastoma summary
Neuroblastoma accounts for 8–10% of all childhood cancers, but is
responsible for more than 15% of childhood cancer deaths [156]. In
order to improve this latter statistic, many targeted agents are being
tested in neuroblastoma patients, and their clinical trial outcomes are
eagerly awaited. To date, ALK inhibitors show promise in the patient
subset whose tumors bear ALK alterations, and substantial efforts are
being made to target MYCN and its downstream targets. The use of
anti-GD2 antibodies in combination with immunomodulators repre-
sents a major advance in the treatment of high-risk neuroblastoma,
and the control of minimal residual disease [89,90].
2.3. CNS tumors
Pediatric brain tumors represent the secondmost common neoplastic
disease of childhood. The main categories of childhood CNS tumors are
gliomas, including low- and high-grade astrocytomas and ependymomas,
and embryonal tumors, such as medulloblastoma, CNS primitive neuro-
ectodermal tumors and atypical teratoid/rhabdoid tumors (AT/RTs)
[157]. Of all childhood cancers, malignant brain tumors are the most sig-
niﬁcant in terms of mortality and morbidity, and would greatly beneﬁt
frommore targeted therapeutic approacheswith less long-term toxicities
[158].
2.3.1. Temozolomide
Temozolomide is an oral DNAdamaging (alkylating) agent approved
for the treatment of astrocytoma andmelanoma in adult patients [159].
Testing for epigenetic silencing of O-6-methylguanine-DNA methyltrans-
ferase (MGMT, encoding a DNA repair protein) predicts which adult pa-
tients will receive the greatest beneﬁt from temozolomide treatment
[160]. Randomized trials in adult glioblastoma multiforme patients
have shown a small but signiﬁcant survival advantage when temozolo-
mide was added to radiation therapy [161]. Similar studies have not
been performed in the pediatric setting, but given the poor prognosis
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the use of temozolomide has become standard of care.
Temozolomide has shown anti-tumor activity in pediatric low grade
gliomas, where single-agent temozolomide induced disease stabiliza-
tion in children with progressive low-grade glioma [162]. However,
no signiﬁcant activity was demonstrated for temozolomide in the
most aggressive glioma of childhood, diffuse intrinsic pontine glioma
(DIPG) [163]. Moreover, temozolomide in combination with the
MGMT inhibitor O-6-benzylguanine (O6-BG), although safe [164], did
not achieve the target response rate for activity in pediatric patients
with recurrent or progressive gliomas [165]. To allow dose escalation
of temozolomide while minimizing bone marrow toxicity, a phase I
trial (NCT01269424) has been initiated for adult glioblastoma
multiforme patients. Here, O6-BGwill be combinedwith infusion of au-
tologous hematopoietic stem cells transduced with a lentiviral vector
encoding a mutant form of MGMT P140K resistant to O6-BG, which
may reduce the bone marrow side-effects of temozolomide. Favorable
results using a similar approach have already been reported for 3 glio-
blastoma multiforme patients, who all exceeded the median expected
survival [166]. A similar phase I trial enrolling patients aged 1–
21 years with recurrent or progressive brain tumors, or DIPG, is now
underway in Australia (ACTRN12612000535875). These trials will pro-
vide valuable indications as to whether gene therapy approaches can
improve outcomes in CNS tumor patients treated with temozolomide.
2.3.2. Poly(ADP-ribose) polymerase (PARP) inhibitors
Inhibitors of poly(ADP-ribose) polymerase (PARP) prevent the re-
pair of single-strandedDNAbreaks, andmay produce synthetic lethality
in cells with DNA repair defects, or other forms of DNA damage. Temo-
zolomide in combination with the PARP inhibitor AG-014700 proved
active in medulloblastoma xenografts, with sustained tumor regression
being achieved in theD425MedMGMT-negativemodel [167]. The PARP
inhibitor olaparib also sensitized pediatric high-grade glioma, medullo-
blastoma and ependymoma cell lines to radiotherapy in vitro, albeit at
micromolar concentrations [168]. Clinical trials involving pediatric
brain tumor patients are now combining radiotherapy and/or temozo-
lomide with the PARP inhibitors veliparib (NCT01514201) or ABT-888
(NCT00946335).
2.3.3. Sonic hedgehog (SHH) inhibitors
The secreted SHH ligand is a morphogenic protein that signals
through the smoothened (SMO) receptor, inducing proliferation of neu-
ronal precursor cells. As medulloblastoma has been classiﬁed into Wnt,
sonic hedgehog (SHH), Group 3 and Group 4 subgroups, according to
molecular features [169], SHH antagonists represent exciting novel
prospects for treating a sub-set of medulloblastoma patients. LDE-225
(erismodegib) is a potent and selective SMO antagonist that also led
to acquired resistance during treatment of medulloblastoma xenografts
[170]. However, LDE-225 used in combination with the PI3K inhibitor
NVP-BKM120, or the dual PI3K–mTOR inhibitor NVP-BEZ235, markedly
delayed the development of resistant disease, and may provide an efﬁ-
cient way to treat refractory and relapsed medulloblastoma patients
[170]. Vismodegib (GDC-0449) is another SHH inhibitor that has in-
duced tumor regression in mouse medulloblastomas and xenografts
[171–174], and dramatic anti-tumor effects in a relapsed medulloblas-
toma adult patient [175]. More recent preclinical in vivo studies
highlighted potential roles for novel SHH inhibitors such as SEN450
and PF-5274857 in treating gliomas and medulloblastoma [176,177].
SEN450 showed anti-proliferative activity as a single agent, and further
reduced tumor size after temozolomide pretreatment in an adult glio-
blastoma xenograft model [176]. PF-5274857 effectively penetrated
the blood–brain barrier in mice bearing medulloblastoma xenografts,
and produced better survival rates than vehicle-treated mice [177]. Vis-
modegib is now in phase I (NCT00822458) and phase II (NCT00939484,
NCT01239316) clinical trials for medulloblastoma treatment, and in
phase II trial for DIPG (NCT01774253). Temozolomide and LDE-225are currently in phase III trial for the treatment of relapsedmedulloblas-
toma (NCT01708174).
2.3.4. PI3K/mTOR inhibitors
Several trials have been reported or are ongoing for the use of
rapamycin and other derivatives for childhood brain tumors. Rapamycin
in combination with erlotinib induced prolonged disease stabilization in
2/19 (10.5%) low-grade glioma patients [178], while everolimus as a sin-
gle agent produced tumor volume reductions in 65–79% tuberose sclero-
sis patients with subependymal giant cell astrocytoma [179]. After
obtaining encouraging results in a pre-clinical medulloblastoma mouse
model, temsirolimus entered phase I and II trials for pediatric solid tu-
mors [98,99], where itwaswell tolerated as amonotherapy, and induced
disease stabilization in 7/17 (41%) high-grade gliomapatients [99]. Other
molecules evaluated for the treatment of pediatric CNS tumors and
active against the PI3K/mTOR pathway include perifosine, XL147
(SAR245408) and torkinib (PP242). Perifosine was tested in a PDGFRA-
overexpressing mouse model of high-grade brainstem glioma as either
amonotherapy, or in combinationwith radiation, but did not signiﬁcant-
ly improve survival relative to either no treatment, or radiation alone
[180]. Similarly, XL147 was tested against 8 CNS tumor xenografts but
demonstrated at best modest activity [32].
2.3.5. MAP kinase pathway inhibitors
The Ras/Raf/MEK/ERK axis is abnormally activated in pediatric can-
cers by mutations in BRAF and KRAS genes. Multiple inhibitors of this
pathway, including selumetinib and tipifarnib, have been tested in the
context of pediatric CNS tumors since the BRAF V600Emutation was re-
cently identiﬁed as a driving factor in subsets of pediatric low grade gli-
omas [181]. Although selumetinib showed limited in vitro and in vivo
activity as a single agent in a panel of 44 pediatric xenograft models
[182], it was highly active against a juvenile pilocytic astrocytomaxeno-
graft (BT-40) harboring the BRAF V600Emutation, causing complete re-
gressions [182]. Selumetinib is now in phase I clinical trial for recurrent
or refractory low-grade gliomas (NCT01089101). Tipifarnib, a Ras
farnesyltransferase inhibitor, was evaluated in a phase I trial for refrac-
tory sarcomas and brain tumors or neuroﬁbromatosis, where it was
well tolerated in children but showed limited activity [183]. In a more
recent trial of newly diagnosed DIPG patients, tipifarnib administered
with irradiation offered no clinical advantage above irradiation alone
[184], although Ras status (presence of mutations, or aberrant activity
in tumors) was not reported.
2.3.6. Monoclonal antibody therapy
Cetuximab is a mAb directed against EGFR, and approved for treat-
ment of KRAS wild-type metastatic colorectal cancer, and squamous
cell carcinoma of the head and neck. The combination of cetuximab
and irinotecan proved safe in children and active against CNS tumors
[185], leading to ongoing phase II evaluation in high-grade astrocyto-
mas and DIPG, in combination with radiotherapy (NCT01012609). Re-
cently, a case report described intra-arterial cerebral infusion of
cetuximab and bevacizumab (a monoclonal VEGF antibody) for multi-
ply recurrent pediatric ependymoma, producing stable residual disease
[186]. Another EGFR mAb used to treat pediatric brain tumors is
nimotuzumab, which could be safely administered over long periods,
andwas associatedwith improved survival in 23 high-grade glioma pa-
tients [187]. The potential use of nimotuzumab in radioimmunotherapy
(when conjugated to (177)Lu) was also recently tested in A431 epithe-
lial carcinoma xenografts, where locoregional application demonstrat-
ed antitumor activity [188]. Less encouragingly, discordant responses
in adult versus pediatric high-grade glioma patients have been reported
for bevacizumab. Adults with recurrent high-grade glioma treated with
bevacizumab and irinotecan achieved radiographic responses in 20/32
(63%) cases [189], whereas only 2/12 (16.7%) pediatric patients
achieved a partial response, and 5/12 (45.5%) experienced diffuse inva-
sive recurrence [190]. Similarly, a phase II study of the combination of
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ependymoma showed disease stabilization in 2/13 (15.4%) patients
[191]. On the other hand, the same combined therapy produced objec-
tive responses with clinical improvements in 7/9 pediatric low-grade
gliomas [192].
2.3.7. Tyrosine kinase inhibitors
A number of small molecule EGFR inhibitors have been tested in chil-
dren with CNS tumors. Erlotinib in combination with rapamycin pro-
duced prolonged disease stabilization in 2/19 (10.5%) low-grade
glioma patients [178]. Erlotinib was also tested in combination with ra-
diotherapy in two independent phase I trials for high-grade gliomas
and astrocytomas. The ﬁrst study reported no objective radiologic re-
sponses to therapy, but prolonged disease stabilization in 16/23 (70%)
patients [193], while the second reported that 4/18 (22%) patients
achieved partial responses [194]. A phase I trial of erlotinib in combina-
tion with temozolomide produced stable disease or partial response in
2/13 (15%) patients with CNS tumors [110]. Geﬁtinib is an EGFR/ERBB2
inhibitor that has been proposed for the treatment of malignant gliomas,
brain stem tumors and medulloblastoma following preclinical results
using mouse xenografts [195]. Phase I trials have indicated that geﬁtinib
is well tolerated in children as a single agent, and in combination with
irinotecan or radiotherapy [196]. A more recent phase II clinical trial of
geﬁtinib and radiotherapy in brainstem gliomas indicated partial re-
sponses in 6/43 (14%) patients, and long-term progression-free survival
in this usually fatal disease [197]. Another dual EGFR/ERBB2 inhibitor
lapatinib proved safe and induced prolonged stable disease in 13/59
(22%) CNS tumor patients [198]. Through a cytotoxicity screening ap-
proach, lapatinib also demonstrated antitumor activity against AT/RT
cell lines in vitro andxenografts in vivo [199]. Another EGFR/ERBB2 inhib-
itor, AEE788, produced prolonged survival and tumor growth suppres-
sion in xenograft models of ependymoma [200] and medulloblastoma
[201], respectively.
Other tyrosine kinases such as VEGFR, PDGFR andMET are potential
therapeutic targets for pediatric CNSmalignancies, due to their aberrant
activation in pediatric brain tumors [202,203]. However, the VEGFR
inhibitors sunitinib and vandetanib gave disappointing results in
childhood brain cancer clinical trials. In particular, sunitinib showed
cardiotoxicity in children with previous exposure to anthracyclines or
cardiac radiation [204], whereas vandetanib in combinationwith radio-
therapy induced longer progression-free survival in only 3/35 (8.5%)
DIPG patients [205]. Recently, a combination of VEGFR and PDGFR in-
hibitors (vandetanib and dasatinib) did not improve the poor prognosis
of newly diagnosed DIPG patients, who showed 2-year survival rates of
less than 10% [206]. TheVEGFR inhibitor cediranib (AZD2171) produced
tumor growth delay in 1/3 medulloblastoma xenografts when adminis-
tered as a monotherapy [120], but showed additive effects with
rapamycin and vincristine towards D645 xenografts [121]. A phase I
clinical trial in children with recurrent or progressive CNS tumors is
nonetheless underway (NCT00326664). Foretinib, amulti-kinase inhib-
itor ofMET and PDGFRA, reduced tumor growth andmetastasis in xeno-
graftmodels of disseminatedmedulloblastoma [207], whereas thepolo-
like kinase (PLK1) inhibitor BI2536 suppressed cell growth and en-
hanced radiation sensitivity in 5 medulloblastoma cell lines (ONS-76,
Daoy, D283, D425 and D458) [208].
2.3.8. DNA topoisomerase inhibitors
A number of DNA topoisomerase inhibitors have shown activity in
the treatment of childhood CNS malignancies. Topotecan in particular
produced complete or partial responses in 10/36 (28%) newly diag-
nosed high-risk medulloblastoma patients [209], and consolidated re-
mission of poor prognosis pediatric CNS tumors when combined with
carboplatin [210]. Twophase II trials of topotecan as part of combination
therapy in high-risk pediatric brain tumors are currently underway
(NCT01342237, NCT01756989). Similarly, irinotecan as a monotherapy
proved active in children with relapsed CNS tumors, producing partialor complete responses in subsets of glioma [211] and medulloblastoma
patients [212], and objective responses in children with recurrent me-
dulloblastoma when combined with bevacizumab [213]. Etoposide in
combination therapy has also successfully completed phase I [214]
and II trials [215] for pediatric CNS tumors, with 22/28 (79%) patients
showing complete or partial responses to carboplatin, etoposide, and
high-dose methotrexate [215]. As described for neuroblastoma, investi-
gational topoisomerase poisons such as namitecan and Genz-644282
have produced some encouraging results in the preclinical setting. In
the PFSK primitive neuroectodermal tumor xenograftmodel, namitecan
treatment induced complete responses and prevented tumor relapse,
but only slowed tumor growth in medulloblastoma Daoy xenografts
[147], whereas Genz-644282 produced partial regression of D645 glio-
blastoma xenografts, but progressive disease inmice bearing BT-45me-
dulloblastoma xenografts [216].
2.3.9. HDAC and Aurora kinase inhibitors
As in leukemia and neuroblastoma, HDAC inhibitors have also dem-
onstrated activity against pediatric CNS tumors. The anticonvulsant
valproic acid was tested in a phase I study in patients with refractory
solid or CNS tumors, and gave partial or minor responses in single pa-
tientswith glioblastomamultiforme and brainstemglioma, respectively
[217]. This led to further phase II studies in combinationwith radiother-
apy and bevacizumab (NCT00879437). Entinostat decreased prolifera-
tion and potentiated the effects of ionizing radiation in AT/RT tumor
cell lines [218], while both panobinostat and vorinostat showed tumor
growth inhibition and radio-sensitization in the HD-MB03 medullo-
blastoma mouse model [219]. Phase I trials of vorinostat as either a
single agent [38], or in combination with temozolomide [220] or
bortezomib [135] produced cases of disease stabilization, but no objec-
tive responses. Vorinostat was also tested in combination with the
AURKA inhibitor alisertib, showing additive cytotoxicity in Daoymedul-
loblastoma cells [134]. The importance of Aurora kinases as potential
therapeutic targets for childhood brain malignancies is highlighted by
AURKB being highly and consistently overexpressed in the majority of
high-grade glioma (8/11) and DIPG (6/9) patients [221]. Alisertib
alone also produced objective responses in medulloblastoma and glio-
blastoma xenografts, including a maintained complete response (BT-
46 cells) and a partial response (D456 cells) [35].
2.3.10. Hsp90 inhibitors
Hsp90 inhibitors represent candidate agents for the treatment of pe-
diatric brain tumors. In the preclinical setting, geldanamycin and its an-
alog 17AEP-GA showed potent inhibition of adult LN18, LN229 and
T98G glioblastoma cell proliferation, survival, migration and invasion
in vitro [222]. NVP-AUY922, a synthetic Hsp90 inhibitor, also strongly
inhibited the proliferation of pediatric SF188 and KNS42 glioblastoma
cell lines [223]. Recently, another Hsp90 inhibitor ganetespibwas tested
on the BRAF-mutant BD-40 astrocytoma xenograft model, but showed
no antitumor activity [40]. In a phase I trial for 17AAG in patients with
relapsed/refractory solid tumors, the best response was stable disease
in 5/17 (29%) patients, including 1/4 ependymoma patients [224].
2.3.11. CNS tumor summary
In addition to poor survival rates, CNS tumors are associated with
signiﬁcant long-term neurologic effects in survivors that result from
radio- and chemotherapy. Targeted agents with an improved therapeu-
tic window could spare normal cells in the developing brain, and even
agents delaying radiotherapy treatment could signiﬁcantly reduce ad-
verse long-term effects [225]. Although anti-tumor activity in pre-
clinicalmodels has not always been conﬁrmed in early phase clinical tri-
als, these results may not reﬂect those that could be obtained at initial
diagnosis. In summary, the signiﬁcant recent advances in our under-
standing of themolecular changes driving pediatric CNS tumors require
more time to fulﬁll their promise in the clinic.
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Pediatric sarcomas are a heterogeneous group of neoplasms charac-
terized by speciﬁc chromosomal translocations (Ewing sarcoma, syno-
vial sarcoma and ARMS) [226], or complex karyotypes and gains of
whole chromosomes (osteosarcoma and ERMS) [227,228].
2.4.1. Ewing sarcoma
Ewing sarcoma is a rare tumor of bone or soft tissues, and is charac-
terized by the fusion of the EWS gene to those encoding the transcrip-
tion factors FLI1 or ERG in 85% and 10% of cases, respectively [229].
Multiple targets have been demonstrated for EWS/FLI1, including IGF
binding protein 3 (IGFBP-3) [230], which increases IGF-1 bioavailability,
and the Aurora kinases [231].
2.4.1.1. Insulin-like growth factor type 1 receptor (IGF-1R) inhibitors. As
EWS translocations activate the IGF pathway, inhibition of insulin-like
growth factor type 1 receptor (IGF-1R) function may target Ewing sar-
coma [232]. However, despite encouraging pre-clinical data [233,234],
clinical trial results for IGF-1R targeted agents have been disappointing
[232]. A phase I trial of AMG 479, a mAb targeting IGF-1R induced
partial or complete responses in Ewing sarcoma patients [235], but
more recent phase II trials using similar agents such as R1507 [236],
ﬁgitumumab [237] and cixutumumab [238] reported only partial re-
sponses in patients with recurrent or refractory disease. A limitation
of these trials however was that patients were not selected on the
basis of IGF-1R expression. Several trials are currently evaluating the
activity of novel IGF-1R antibodies such as teprotumumab as a mono-
therapy (NCT00642941), or in combination with mTOR inhibitors
(NCT00880282, NCT00927966).
2.4.1.2. Aurora kinase inhibitors.Although the AURKA inhibitor alisertib
induced complete responses in 1/5 Ewing sarcoma xenograft models
(SK-NEP-1) [35], single-agent alisertib only stabilized disease in a
phase I trial that included Ewing sarcoma patients [133]. A phase II
trial has recently been completed, although results are not yet avail-
able (NCT01154816). The pan-Aurora kinase inhibitor tozasertib
was shown to selectively and potently reduce the viability of Ewing
sarcoma cell lines, and demonstrated synergies with etoposide and
doxorubicin [239]. Dual inhibition of AURKA and AURKB in Ewing
sarcoma may therefore be more potent than AURKA inhibition
alone [239].
2.4.1.3. Other tyrosine kinase inhibitors. Surface expression of c-KIT and
PDGFRΒ in Ewing sarcoma cell lines predicted that Ewing sarcoma
may respond to imatinib,which produced concentration-dependent in-
hibition of cell growth in vitro in multiple Ewing sarcoma cell lines, and
of tumor growth in vivo [240]. However, single-agent imatinib pro-
duced disappointing results in phase II clinical trials, with only 1/24
(4%) [241] or 1/5 [242] Ewing sarcoma/PNET patients achieving partial
responses. This occurred despite the immunohistochemical detection of
KIT or PDGFRΑ being a requirement for patient selection in one trial
[242]. The multi-targeted kinase inhibitor pazopanib induced tumor
growth delay as the best response in 5 Ewing sarcoma xenografts
[243], while cediranib showed modest anti-tumor activity as a single
agent, but additive effects against EW5 cells in combination with
rapamycin [121]. Dasatinib inhibited proliferation without inducing
apoptosis in 3 Ewing sarcoma cell lines [124], whereas geﬁtinib and
vandetanib inhibited cell line proliferation at only micromolar concen-
trations [244], indicating that Ewing sarcomas may not depend on
EGFR and VEGFR pathways for survival [244]. More recently, MET and
ALK mutations were demonstrated in Ewing sarcomas, and in vitro
treatment of ﬁve patient-derived cell lines with MET and/or ALK inhib-
itors produced IC50 values within the lowmicromolar range [245]. Fur-
ther research will be required to determine whether MET/ALKinhibitors could be used to treat a subset of Ewing sarcoma patients
[245].
2.4.1.4. HDAC and Hsp90 inhibitors. The HDAC inhibitor entinostat (MS-
27-275) showed in vitro cytotoxicity in Ewing sarcoma cell lines, and
marked regression of established TC71 Ewing sarcoma xenografts
[137]. More recently, vorinostat induced signiﬁcant tumor growth
delay in 3/5 Ewing xenograft models, but no objective responses
[246], and no objective responses in combination with bortezomib in
a subsequent phase I clinical trial [135]. Similarly, both theHsp90 inhib-
itors ganetespib [40] and AT13387 [247] produced little anti-tumor ac-
tivity and no objective responses in 2 and 5 Ewing sarcoma xenograft
models, respectively [40,247].
2.4.1.5. DNA topoisomerase inhibitors. Encouraging results have come
from the testing of TOP1 and TOP2 inhibitors, where irinotecan and
etoposide were both well-tolerated and active in high-risk or refracto-
ry/relapsed Ewing sarcoma patients in combination regimes [248,249].
Topotecan in combination with cyclophosphamide induced stable dis-
ease or partial responses in 4/13 (31%) and 3/13 (23%) relapsed Ewing
sarcoma patients, respectively [250], while objective responses were
attained in 7/14 (50%) patients with recurrent or progressive disease
when vincristinewas added to the protocol [251]. In vivo studies also re-
vealed that Genz-644283 [216] and namitecan [252] produced main-
tained complete responses in SK-NEP-1 [216] and TC-71 [252] Ewing
sarcoma xenografts at well-tolerated doses.
2.4.1.6. Ewing sarcoma summary. A number of challenges emerge from a
consideration of targeted therapy use in Ewing sarcoma. While targets
and pathways downstream of oncogenic fusion proteins provide a
wealth of therapeutic targets in Ewing sarcoma [226], the clinical bene-
ﬁts from targeted therapy have been limited, and not always been ex-
plained by target expression [242,253]. Limitations to drug diffusion
and penetration in bone may reduce the activity of high molecular
weight agents such as mAbs [253], and the relevance of preclinical
results obtained in subcutaneous xenograftmodels. Intra-tumor hetero-
geneity also makes a strong case for the use of multiple targeted thera-
pies in combination regimes [253].
2.4.2. Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a group ofmalignancies that resemble
developing skeletal muscle, and is the most common soft-tissue sarco-
ma in children and adolescents [228]. RMS is divided into twomajor his-
tologic subgroups, ERMS and ARMS, which account for 60% and 30% of
cases, respectively [228]. ERMS is characterized by chromosome gains
(chromosomes 2, 8, 12, 13) and loss of heterozygosity for chromosome
11p15.5 [228]. In contrast, ARMS is characterized by fusions of the tran-
scription factors PAX3 and PAX7 with FOXO1 in 70% and 10% ARMS
patients, respectively [254]. Great efforts have been made to directly
alter the expression or function of these fusion proteins, through the
use of antisense oligonucleotides [255], transcriptional repressors
[256] and vaccines against the fusion region [257]. As for neuroblastoma
(Section 2.2.2), differentiation therapy has been attempted in RMS cell
lines in vitro. Treatment of RD and Rh30 cells with retinoic acid induced
stereo-speciﬁc growth inhibition, but not differentiation [258], whereas
12-O-tetradecanoylphorbol-13-acetate treatment of RD cells induced
myogenic differentiation [259]. More recently, fenretinide was shown
to reduce PAX3–FOXO1 fusion protein levels in ARMS cell lines, and to
signiﬁcantly delay in vivo tumor growth in ARMS Rh4 xenografts, com-
pared to untreated controls [260].
2.4.2.1. Tyrosine kinase and PI3K/mTOR inhibitors. PAX3/7-FOXO1 down-
stream targets includeMET, PDGFR and IGF/IGFR, so therapies targeting
these molecules or pathways may be useful for RMS treatment. Trans-
genic expression of the MET ligand hepatocyte growth factor in Ink4a/
Arf−/−mice induced RMS with extremely high penetrance and short
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tion and invasiveness in vitro, and induced regression of RD18 xeno-
grafts [262]. High levels of phosphorylated MET were detected in 14/
24 (58%) RMS patient samples and CW9019 and Rh30 ARMS cell lines,
where treatment with the MET inhibitor SU11274 signiﬁcantly
inhibited cell proliferation and migration in vitro [263].
Following the demonstration that PDGFRA is a transcriptional tar-
get of PAX3–FOXO1 [264], PDGFRΑ inhibition using RNA interference
or imatinib reduced mouse ARMS cell line proliferation in vitro, and
imatinib or PDGFRA neutralizing antibody treatment led to disease
regression or stabilization in vivo [265]. The selective PDGFR inhibi-
tor CP-673,451 also reduced tumor volume, Ki67 staining and
PDGFR phosphorylation of RUCH2 xenografts in vivo [266]. The
multi-target tyrosine kinase inhibitor pazopanib delayed growth of
Rh30 xenografts and enhanced survival, both as a single agent and
in combination with topotecan [127]. However when used at a
lower dose, single-agent pazopanib signiﬁcantly improved event-
free survival in only 2/5 ARMS/ERMS xenograft models, and pro-
duced no objective responses [243].
Targeting IGF/IGFR as downstream effectors of PAX3/7–FOXO1 has
been tested using neutralizing antibodies and small molecule inhibitors.
IGF-1R antibodies such as alpha IR-3 [267], IMC-A12 [268], and the IGF-
1R inhibitor BMS-754807 in combination with cetuximab [233] com-
monly inhibited growth of RMS xenografts. In RMS, IGFR survival signal-
ing is primarily maintained through the AKT pathway, and activation of
PI3K/mTOR signaling [269]. Concomitant use of IGFR antibodies and
rapamycin resulted in additive inhibition of Rh30 and RD cell growth
and survival [270], and the PI3K inhibitor XL147 induced tumor growth
delay as a single agent, and signiﬁcantly improved event-free survival in
6/6 RMS xenografts [32]. However a phase II trial of single-agent
temsirolimus induced prolonged stable disease in 1/16 (6%) RMS pa-
tients [99]. IGF-1R can also signal through the MEK/ERK cascade, and
the speciﬁc MEK inhibitor U0126 reduced anchorage-dependent and
-independent RD cell proliferation [271]. U0126 also showed synergistic
interactions with radiotherapy in 3 RMS cell lines in vitro, and signiﬁ-
cantly improved progression free survival of mice bearing TE671 RMS
xenografts [272].
Over 80% of ARMS patients carry altered ALK gene copy number
[273], identifyingALK as a potential therapeutic target in ARMSpatients.
ALK and IGF-1R were subsequently shown to be co-expressed in the
majority of ARMS patient samples examined, and simultaneous
targeting of ALK and IGF-1R (using NVP-TAE684 and the R1507 anti-
body, respectively) produced synergistic effects in the ARMS cell line
Rh41 and Rh30 [274]. A phase I trial (NCT01742286) is now open to
evaluate the safety proﬁle of the ALK inhibitor LDK378 in pediatric can-
cer patients with known ALK alterations. Similarly, a phase II trial
(NCT01524926) is underway to investigate the efﬁcacy of crizotinib in
locally advanced ormetastatic tumors, including ARMS patients harbor-
ing speciﬁc alterations leading to ALK and/or MET activation.
Finally, a number of other kinase inhibitors have been tested in RMS
cell lines and xenografts, such as erlotinib, alisertib and AZD1480, which
are EGFR, Aurora kinase and JAK/STAT inhibitors, respectively. While
primary tumors from a transgenic ARMS model expressed EGFR, these
were unaffected by erlotinib treatment [275]. In contrast, alisertib in-
duced maintained complete responses in Rh65 ARMS xenografts [35,
36], and signiﬁcantly improved event-free survival in 4/5 other RMS xe-
nografts, including Rh18 [35]. Similarly, AZD1480 reduced Rh18 ERMS
cell viability in vitro, signiﬁcantly inhibited tumor growth in vivo, and
signiﬁcantly improved the survival of mice bearing Rh18 xenografts
[132].
2.4.2.2. Hsp90 inhibitors. It is worth discussing the role of Hsp90 inhibi-
tors as potential therapies for RMS, as despite demonstrating little
in vivo antitumor activity against other pediatric tumor types,
alvespimycin induced objective responses in Rh30 ARMS xenografts
[276]. Hsp90 was highly expressed in RMS (SMS-CTR and Rh30) butnot in control cell lines, and geldanamycin and its analogs tanespimycin,
17AEP-GA and 17DMAP-GA reduced RMS cell proliferation, migration
and invasion, and induced apoptosis [277]. In contrast, ganetespib and
AT13387 demonstrated only low activity against a number of RMS xe-
nografts, and produced no objective responses [40,247].
2.4.2.3. DNA topoisomerase inhibitors. As previously described
(Sections 2.1.4 and 2.2.5), topoisomerase inhibitors such as etoposide
have been studied in clinical trials as reinduction or maintenance ther-
apy for pediatric malignancies [278,279]. In relapsed or refractory RMS
patients, irinotecan showed anti-tumor activity and a good tolerance
proﬁle as a single agent [280], as well as additive effects when adminis-
tered with vincristine [281]. Similarly, the combination of topotecan
with vincristine and doxorubicin induced objective responses in a
small cohort of 6 patients with refractory or recurrent RMS, and was
well tolerated [282]. More recent in vivo studies also indicated that
namitecan, Genz-644282 and gimatecanwere highly active in a number
of RMS xenograft models [148,216,252]. As described for Ewing sarco-
ma (Section 2.4.1.5), namitecan produced RD/TE-671 RMS xenograft re-
gression at low doses and additive effects with the antiangiogenic
agents bevacizumab and sunitinib [252], while Genz-644282 induced
complete responses in Rh18 andRh28ARMSandRh30 ERMS xenografts
[216]. Prolonged daily treatment with low doses of gimatecan also pro-
duced signiﬁcant tumor regression in RD/TE-671 RMS tumor xenografts
[148].
2.4.2.4. RMS summary.Outcomes in childrenwith RMS vary greatly, from
95% to 15% 5 year event-free survival for patients with low- or high-risk
disease, respectively [283]. Future clinical trials using targeted therapy
must therefore focus upon improving outcomes for intermediate- and
high-risk patients [283].Whilemany agents have been tested in the pre-
clinical RMS setting, patient numbers limit those that can progress to
clinical trial, particularly in the case of low frequency targets. However
there is optimism that agents such as IGF-1R mAbs and ALK inhibitors
may shortly deliver long-awaited improvements in outcomes for RMS
patients.
2.4.3. Synovial sarcoma
Synovial sarcoma is themost common non-RMS soft tissue sarcoma
in adolescents, and is characterized by translocations that fuse SS18
(SYT) to SSX1, SSX2, and, more rarely, to SSX4 [226]. As such, SS18 fusion
proteins represent a major therapeutic target in synovial sarcoma, and
siRNA down-regulation of SS18–SSX transcripts reduced anchorage-
independent growth of synovial sarcoma cell lines in vitro, and signiﬁ-
cantly delayed tumor formation in vivo [284]. Expression microarray
proﬁling of synovial sarcomas bearing SS18–SSX translocations identi-
ﬁed IGFBP2, ERBB2 and BCL-2 up-regulation [285], with overexpression
of these and other proteins such as EGFR being conﬁrmed by immuno-
histochemistry [285–287]. Whereas treatment of synovial sarcoma cell
lines with the IGF-1R inhibitor NVP-AEW541 impaired cell growth
and signiﬁcantly increased apoptosis [288], a phase II trial of geﬁtinib
in patients with advanced EGFR-positive synovial sarcoma produced
only stable disease as the best response [289]. Following frequent BCL-
2 detection in synovial sarcoma [285–287], the BCL-2 antisense oligonu-
cleotide (G3139) was tested against FU-SY-1 synovial sarcoma cells
in vitro, resulting in signiﬁcantly increased sensitivity to doxorubicin
treatment [290]. In a phase I trial, G3139 induced prolonged stable dis-
ease in 2/5 synovial sarcoma patients in combination with doxorubicin
and cyclophosphamide [291]. In summary, these results suggest that
continued attempts to target either SS18–SSX fusion proteins and/or
their downstream targets are likely to improve outcomes in patients
with this rare tumor type [226].
2.4.4. Osteosarcoma
Osteosarcoma is a primary bone malignancy characterized by het-
erogeneous genetic complexity [227], but as with other childhood
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ERBB2 and Wnt pathways [292].
2.4.4.1. Tyrosine kinase inhibitors. Several studies have evaluated the ef-
fects of IGF-1R inhibition on childhood osteosarcoma cell lines and xe-
nografts. The IGF-1R small molecule inhibitor picropodophyllin
dramatically reduced in vitro colony formation by osteosarcoma cell
lines [293], while NVP-AEW541 [234] and the mAb SCH-717454
(Robatumumab) delayed osteosarcoma xenograft growth either as
monotherapy [294,295], or in combination with cyclophosphamide
[295]. The IGF-1 receptor antagonist RG1507 subsequently produced
stable disease in 2/3 osteosarcoma patients during a larger phase I
trial in children with refractory or relapsed solid tumors [296].
EGFR inhibitors have also been tested in osteosarcoma cell lines,
where the EGFR inhibitor 324674 (a 4,6-disubstituted pyrimidine) re-
duced migration and colony formation of 5/5 and 3/3 osteosarcoma
cell lines, respectively, and the invasiveness of 143B cells [293]. Howev-
er, the EGFR inhibitors geﬁtinib and afatinib did not reduce the viability
of 4 osteosarcoma cell lines in a dose-responsive manner [297]. Al-
though ERBB2 expression has been variably reported in pediatric osteo-
sarcoma [298], ERBB2 positivity has been associated with reduced
event-free and overall survival in osteosarcoma patients [299]. Howev-
er, trastuzumab in combination with cytotoxic chemotherapy did not
improve outcomes in metastatic osteosarcoma patients with ERBB2-
positive disease, relative to those of ERBB2-negative patients not receiv-
ing trastuzumab [300].
Osteosarcoma primary cultures [301] and cell lines [302] have been
reported to express PDGFRA and/or PDGFRB and to respond to PDGF
stimulation in vitro [301,301]. Nonetheless, imatinib inhibited cell
proliferation in vitro at only micromolar concentrations in PDGFR-
expressing patient-derived osteosarcoma cells [301] and MG-63 cells
[302], and a phase I trial of single-agent imatinib produced no responses
in 10 patients with refractory/relapsed osteosarcoma [241]. Other
PDGFR inhibitors have been tested in osteosarcoma, with pazopanib
in combination with topotecan inhibiting the growth of KHOS xeno-
grafts [127], whereas in a phase I study, sunitinib induced stable disease
in one of 2 osteosarcoma patients, but no objective responses [204].
Cediranib (a VEGFR inhibitor) produced complete responses in 1/5 os-
teosarcoma xenografts [120] and showed additive effects with cisplatin
and rapamycin [121].
Other kinases may have particular signiﬁcance in osteosarcoma, and
further therapeutic application. For example, MET overexpression con-
verted primary human osteoblasts into osteosarcoma cells that
displayed the transformed phenotype in vitro, and distinguishing fea-
tures of human osteosarcomas in vivo [303]. The MET inhibitors K252a
[304] and SU11274 [293] reduced HGF-induced cell proliferation and
migration of Saos-2 and U2OS osteosarcoma cell lines [304], and re-
duced MNNG cell migration, and colony formation by TE85, 143B and
MNNG cells [293], respectively. siRNA screening demonstrated the sen-
sitivity of osteosarcoma cell lines towards PLK1 depletion [305], and the
PLK1 inhibitor GW843682X inhibited proliferation of MNNG–HOS and
OST osteosarcoma cell lines that were described as highly resistant to
standard anticancer drugs such as doxorubicin and cisplatin [123].
2.4.4.2. Notch andWnt pathway inhibitors.Notch signaling is upregulated
in primary osteosarcoma samples and cell lines, and genetic or chemical
down-regulation of Notch signaling both signiﬁcantly reduced the
growth of SJSA-1 xenografts in vivo [306]. The γ-secretase and Notch
pathway inhibitors RO4929097 and PF-03084014 delayed in vivo
tumor growth in 4/6 [307] and 5/5 [308] osteosarcoma xenografts, but
produced no objective responses.Wnt signaling controls bone develop-
ment and regeneration, and overexpression of numerousWnt pathway
components have been reported in osteosarcoma [309]. For example,
Wnt10b ligand was detected in 33/44 (75%) osteosarcoma cases and
showed a trend towards association with reduced overall survival
[310]. Inhibition ofWnt/β-catenin signaling with CCT036477 enhancedSaos2 cell line sensitivity to methotrexate, and showed synergistic ef-
fects with Notch inhibition [311]. Targeting the Wnt pathway using re-
combinant proteins, small molecules, antibodies, or via downstream
transcriptional targets are all in preclinical development [309], although
no agents are yet in clinical trial for osteosarcoma.
2.4.4.3. PI3K/mTOR inhibitors. Inhibition of the PI3K/AKT/mTOR axis has
also been proposed for osteosarcoma patients, and PI3K/AKT inhibitors
such as GSK690693 and MK-2206 have been tested against osteosarco-
ma xenograft panels. Both agents signiﬁcantly improved event-free sur-
vival in 6/6 osteosarcoma xenografts in vivo as single agent therapy, but
produced no objective responses [312,313]. More encouragingly,
rapamycin induced maintained complete responses in OS-33 osteosar-
coma xenografts in vivo [314]. Its derivative everolimus, in combination
with sorafenib, also showed antiproliferative and proapoptotic effects,
producing tumor growth inhibition, antiangiogenic and antimetastatic
effects in the MNNG–HOS xenograft model [315]. Phase II studies of
everolimus in children and adolescentswith refractory or relapsed oste-
osarcoma (NCT01216826) are ongoing, and of sorafenib and everolimus
in relapsed and non-resectable osteosarcoma (NCT01804374).
2.4.4.4. Hsp90, HDAC and DNA topoisomerase inhibitors. As for neuroblas-
toma [154], Hsp90 inhibitors have shown interesting results towards
osteosarcoma cells in vitro. Geldanamycin inhibited osteosarcoma U-
2OS and Saos-2 cell proliferation at micromolar concentrations [154],
although U-2OS cells were markedly more sensitive to the analog
SNX-2112 [155]. Both agents demonstrated synergism with cisplatin
[154,155]. HDAC inhibitors such as FR901228 and trichostatin A dem-
onstrated activity towards osteosarcoma cells in vitro and in vivo, partic-
ularlywhen used in combination therapy [316,317]. TheHDAC inhibitor
MS-27-275 also increased apoptosis and promoted regression of lung
metastases in osteosarcoma xenografted mice, with no evidence of sig-
niﬁcant toxicity [318]. Vorinostat produced prolonged stable disease in
one of 2 osteosarcoma patients in a phase I trial, without major toxic-
ities [38], and is under further evaluation in pediatric oncology patients
(NCT01422499). Investigational TOP1 and TOP2 inhibitors recently
demonstrated high activity in osteosarcoma xenografts, with objective
responses to Genz-644284 in 4/5 osteosarcoma xenografts that includ-
ed 2 maintained complete responses [216], and complete responses to
namitecan in U2-OS xenografts [252].
2.4.4.5. Osteosarcoma summary. Osteosarcoma patient outcomes have
failed to improve substantially over the past decades, due to low disease
prevalence combined with high degrees of tumor heterogeneity [214,
319]. Most targets will therefore be present at low frequency, and pri-
mary and secondary resistance to targeted agents will be common. Dis-
ease heterogeneity also presents difﬁculties in extrapolating preclinical
results obtained in small numbers of cell lines or patient xenografts, al-
though limited drug penetration may also explain why encouraging
preclinical results from subcutaneous osteosarcoma xenografts have
not been recapitulated in subsequent phase I trials. More rigorous pre-
clinical testing prior to phase I trial initiation is therefore required
[319]. Targeting metastatic progression as opposed to existing lesions
may also improve outcomes in osteosarcoma patients [320]. Such
targeted agents might show no activity against established lesions,
and would require the use of different experimental and clinical trial
end-points, but could potentially be applied to a number of solid tumors
[320].
3. Conclusions
The use of tailored treatments has already proven successful in the
management of adult cancer patients. Von Hoff and colleagues demon-
strated the achievement of longer progression free survival in 27% of pa-
tients with refractory solid tumors treated with drugs suggested by
molecular proﬁling [321]. More recently, Kim et al. described the
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tumor responsiveness in heavily pre-treated advanced NSCLC patients
[322].
Results from early clinical trials demonstrate that the use of molecu-
larly targeted therapies is generally safe in the pediatric population [30,
38,72,114,135,164,185,187,198], and that particular drugs have shown
promising results. Among them, imatinib, dasatinib and sorafenib
were found active in Ph+ ALL, CML and ALL pediatric patients, respec-
tively [11,20,22]. A large number of tyrosine kinase inhibitors including
crizotinib, erlotinib, geﬁtinib and lestaurtinib have been used to treat
childrenwith refractory/relapsed neuroblastoma [108,110,111,114]. Er-
lotinib and geﬁtinib have been successfully employed to treat high-
grade gliomas [193,194,197], while IGFR mAbs show promising results
in pediatric sarcomas [235]. These encouraging results indicate thatmo-
lecularly targeted therapies have great further potential for the treat-
ment of childhood cancers.
Despite these promising results, the literature published to date also
highlights problems that need to be overcome, to fulﬁll the promise of
molecularly targeted therapies for childhood cancer. A large number
of biomarker-matched drugs are tested in clinical trials, and then
dismissed. In general, 90% of novel targeted therapies do not transition
to routine use, despite good results in the preclinical setting [323]. This
can be due to unexpectedly high toxicities, lack of objective efﬁcacy,
and/or because agents present nomeasurable advantages over those al-
ready in use [323]. In terms of preclinical studies, the assumption that
childhood cancer in vivomodels recapitulate the actual disease has not
always proved correct [225,240–242]. Efﬁcacy of targeted therapies
will be greatly inﬂuenced by intra-tumoral heterogeneity, meaning
that more homogenous models such as cell line xenografts may overes-
timate the efﬁcacy subsequently demonstrated in patients [319]. Other
ﬁndings may reﬂect the fact that the efﬁcacy of targeted therapies
cannot always be evaluated using the standard methods used for con-
ventional chemotherapy, due to off-target effects, requirements for
prolonged dosing at lower levels, and general cytostatic rather than cy-
totoxic effects [324]. In otherwords, tumor growth inhibition could rep-
resent a more adequate measurement of activity rather than tumor
regression in the assessment of single agent efﬁcacy, highlighting the
importance of combination trials. This is particularly important in the
pediatric population where the goal must be to eradicate disease in
the long term.
Another challenge is the low frequency at which predictive markers
are often detected in tumors (Table 2), meaning that only a minority of
patients may beneﬁt from a speciﬁc targeted therapy [325,326]. This
problem can become particularly acute in rare diseases such as child-
hood cancers. Efﬁcacy of targeted therapies may be underestimated if
preclinical models do not represent the full range of clinical disease, or
if patients are not appropriately selected in clinical trials [323]. Another
consideration is the presence or development of drug resistance, due to
either activation of alternative pathways, or the presence or acquisition
of further mutations that confer a selection advantage to a subgroup of
cancer cells [327]. In this context, it is important to consider the combi-
nation of multiple agents and/or the use of less selective drugs, in order
to inhibit multiple pathways at the same time, or the same pathways at
multiple levels [328].
In summary, our understanding of altered signaling pathways re-
sponsible for childhoodmalignancies is changing treatment approaches
and improving the outcomes of pediatric patients. A huge effort has
beenmade to prove the safety ofmolecular targeted therapies in the pe-
diatric population, but patient results have sometimes been considered
disappointing. It is clear that conventional methods to evaluate clinical
efﬁcacy of novel therapies do not always apply to targeted agents, due
to the genetic complexity and heterogeneity of tumors, and the modes
of action of these novel drugs. Therefore, the testing of targeted agents
in combination with traditional chemotherapeutics needs further in-
vestment, in order to produce long-lasting clinical beneﬁts. At the
same time, preclinical models need to be improved for the assessmentof optimal dosing to obtain additive effects in combination therapy,
while clinical trials with patient selection based on molecular proﬁling
will avoid administering target-speciﬁc agents to patients who are un-
likely to beneﬁt. Finally, of the 12 known pathways that are aberrantly
activated in cancer, at least 140 different genes have been described to
carry driver mutations [329], but only a small percentage of these are
currently “actionable” in the context of targeted therapy. Identifying
new actionable targets will be essential to expand the beneﬁts of
targeted therapies to a broader range of patients.
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